Immunotherapy targeting the anti-PD-1/PD-L1 axis is used to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (Harrington et al., 2023). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.